Related Experiment Video

Updated: Aug 19, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized

Fernando Gomez-Peralta¹, Cristina Abreu¹, Elsa Fernández-Rubio²

¹Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain.

|November 30, 2022

Abstract

Objective:

To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes.

Research Design And Methods:

This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6-week double-arm phase in which participants were randomly assigned into an active or masked mode.

Results:

Fifty-five participants were evaluable (active group, n = 26, masked group, n = 29). The increase in time in range was higher in the active versus masked group (5.2% vs. -0.8%; P = 0.016). The active group showed a higher reduction in mean glucose, glucose management indicator, time above range, and high blood glucose index. On-time insulin doses increased in the active group and decreased in the masked group.

Conclusions:

Insulclock system use was associated with improved glycemic control, glycemic variability, hyperglycemia risk, and treatment adherence in people with uncontrolled type 1 diabetes.

More Related Videos

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...

Articles linked to this work by shared authors, journal, and citation graph.

Real-World Long-Term Safety of Statin-Fibrate Combination Therapy in Older Patients (≥75 Years): A European Cohort Analysis.

Geriatrics (Basel, Switzerland)·2026

Determinant factors for headache at acromegaly diagnosis: findings from an Iberian multicenter study encompassing 726 patients.

Journal of endocrinological investigation·2026

Weight regain after obesity treatment: mechanisms, predictors, and real-world evidence from the IGOBE program.

Reviews in endocrine & metabolic disorders·2026

Improvement in insulin injection timing and glucometrics using a connected insulin cap: the Insulclock v2.0® prospective study.

Frontiers in endocrinology·2026

Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study.

The lancet. Diabetes & endocrinology·2026

Implementation of Intermittently Scanned Continuous Glucose Monitoring and Changes in Hospitalizations and Health Care Costs in Insulin-Treated Type 2 Diabetes.

Diabetes care·2026

See all related articles